Pipeline Applications Sample Clauses

Pipeline Applications. 21 4.25 Contracts..................................................................................... 21 4.26 Accuracy of Information Furnished by the Company, or the Shareholders.................................................................................. 21 4.27 Investment Intent; Sophisticated Investor Status; Market for Purchaser........................ 22 4.28
View Source
Pipeline Applications. SCHEDULE 4.24 sets forth all of the mortgage loan applications that are currently being processed by the Company.
View Source
Pipeline Applications. Schedule 4.23(v)(3) sets forth, as of the date indicated thereon, (A) the last name of each applicant who has submitted a Pipeline Application, provided that the Pipeline Application is then in force and has not resulted in a closed loan; (B) the loan amount, (C) the interest rate on the loan, (D) the origination date of the loan, (E) the approval date of the loan, (F) the lien status of the loan and (G) the property address (including the state) where the Mortgage Collateral securing such loan is located. In the case of any of the Pipeline Applications that have been approved by the Borrower or a Subsidiary of the Borrower, there are and will be no terms or conditions relating to such Pipeline Application that will prevent the Borrower or any Subsidiary of the Borrower from timely making any required disclosures or otherwise complying with all applicable law.
View Source
Pipeline Applications. To the Knowledge of Seller, Section 4.20 of the Disclosure Schedule sets forth, as of the date hereof, the name and address of each potential borrower who has submitted a Pipeline Application for review, provided that the Pipeline Application is then in force and has not resulted in a closed loan, the name of the originating loan officer, broker or correspondent responsible for taking the Pipeline Application, the name of the intended Investor, if any, the type of loan program and the rate which the Company or any of the Company Subsidiaries has committed to the related borrower, the expected loan amount, the fees the Company or Company Subsidiary expects to charge the loan officer, broker, correspondent or the borrower to close the underlying Purchased Mortgage Loan, as applicable, and, if known, the closing date, and whether the Pipeline Application has been approved by the Company or Company Subsidiary and whether it constitutes a locked Pipeline Application. To the Knowledge of Seller, except as reflected in the computer records and computer files of the Company, neither Seller, the Company nor any of the Company Subsidiaries has undertaken or agreed to any amendment, revision or modification of any Pipeline Application and all modifications have been made in accordance with all applicable Mortgage Loan Regulations.
View Source
Pipeline Applications. Attached hereto as Section 5.14 Schedule (c)o is a true, complete and accurate list of all Pipeline Applications (other than Pipeline Loans), as of the Closing Date. The employees of the Company originated all Pipeline Applications.
View Source
Pipeline Applications. Schedule 4.1(l) will set forth, as of the date hereof, the Effective Date and as of the Closing Date, the name and address of each potential borrower who has submitted a Pipeline Application for review, provided that the Pipeline Application is then in force and has not resulted in a closed loan, the name of the originating broker responsible for taking the Pipeline Application, the name of the intended Investor, if any, the type of loan program and the rate which Seller has committed to the related borrower, the expected loan amount, the fees Seller expects to charge the broker or the borrower to close the underlying Mortgage Loan, as applicable, and, if known, the closing date, and whether the Pipeline Application has been approved by Seller and whether it constitutes a Locked Pipeline Application. In the case of any of the Pipeline Applications that have been approved by Seller, there are and will be no terms or conditions under the reasonable control of Seller that will prevent Purchaser from timely making any required redisclosures or otherwise complying with all applicable Mortgage Loan Requirements, provided that Purchaser acts in accordance with normal mortgage banking standards and procedures. Except as reflected in the computer records and computer files of Seller, Seller has not undertaken or agreed to any amendment, revision or modification of any Pipeline Application. Any modification has been made in accordance with all applicable Mortgage Loan Requirements.
View Source
Pipeline Applications 
View Source

Related to Pipeline Applications

  • Regulatory Applications (a) Summit and GAFC and their respective Subsidiaries shall cooperate and use their respective reasonable best efforts to prepare all documentation, to effect all filings and to obtain all permits, consents, approvals and authorizations of all third parties and Governmental Authorities necessary to consummate the transactions contemplated by this Agreement. Each of Summit and GAFC shall have the right to review in advance, and to the extent practicable each will consult with the other, in each case subject to applicable laws relating to the exchange of information, with respect to, all material written information submitted to any third party or any Governmental Authority in connection with the transactions contemplated by this Agreement. In exercising the foregoing right, each of the parties hereto agrees to act reasonably and as promptly as practicable. Each party hereto agrees that it will consult with the other party hereto with respect to the obtaining of all material permits, consents, approvals and authorizations of all third parties and Governmental Authorities necessary or advisable to consummate the transactions contemplated by this Agreement and each party will keep the other party apprised of the status of material matters relating to completion of the transactions contemplated hereby. (b) Each party agrees, upon request, to furnish the other party with all information concerning itself, its Subsidiaries, directors, officers and stockholders and such other matters as may be reasonably necessary or advisable in connection with any filing, notice or application made by or on behalf of such other party or any of its Subsidiaries to any third party or Governmental Authority.

  • Mobile Application If Red Hat offers products and services through applications available on your wireless or other mobile Device (such as a mobile phone) (the "Mobile Application Services"), these Mobile Application Services are governed by the applicable additional terms governing such Mobile Application Service. Red Hat does not charge for these Mobile Application Services unless otherwise provided in the applicable additional terms. However, your wireless carrier's standard messaging rates and other messaging, data and other rates and charges will apply to certain Mobile Application Services. You should check with your carrier to find out what plans your carrier offers and how much the plans cost. In addition, the use or availability of certain Mobile Application Services may be prohibited or restricted by your wireless carrier, and not all Mobile Application Services may work with all wireless carriers or Devices. Therefore, you should check with your wireless carrier to find out if the Mobile Application Services are available for your wireless Device, and what restrictions, if any, may be applicable to your use of such Mobile Application Services.

  • General Application The rules set forth below in this Article VI shall apply for the purposes of determining each Member’s allocable share of the items of income, gain, loss and expense of the Company comprising Net Income or Net Loss for each Fiscal Year, determining special allocations of other items of income, gain, loss and expense, and adjusting the balance of each Member’s Capital Account to reflect the aforementioned general and special allocations. For each Fiscal Year, the special allocations in Section 6.03 hereof shall be made immediately prior to the general allocations of Section 6.02 hereof.

  • Provisional Application Upon signature of this Compact, and until this Compact has entered into force in accordance with Section 7.3, the Parties will provisionally apply the terms of this Compact; provided that, no MCC Funding, other than Compact Implementation Funding, will be made available or disbursed before this Compact enters into force.

  • Communications with Regulatory Authorities During the Collaboration Term, Xencor shall provide MorphoSys with reasonable advance notice of any meeting or substantive telephone conference with any Regulatory Authority relating to any Licensed Antibody and/or Licensed Product. MorphoSys shall have the right to attend and observe (but not participate actively in) any material meeting or material conference call with any Regulatory Authority regarding any of MorphoSys (or its Affiliate’s or Sublicensee’s) Licensed Antibody and/or Licensed Products. In addition, Xencor shall promptly furnish to MorphoSys copies of all correspondence that Xencor (or its Affiliate) receives from, or submits to, any Regulatory Authority (including contact reports concerning conversations or substantive meetings) relating to any Licensed Antibody and/or Licensed Product. Xencor shall also provide to MorphoSys any meeting minutes that reflect material communications with any Regulatory Authority regarding a Licensed Antibody and/or Licensed Product. Subject to the provisions of Section 2.2(c)(ii), MorphoSys shall provide in its MorphoSys Annual Development Reports to Xencor, and through JDC discussion, information regarding its (or its Affiliate’s or, to the extent permitted by the Sublicense, Sublicensee’s) interactions with Regulatory Authorities with respect to all Licensed Antibodies and/or Licensed Products in its respective Territory. In addition, to the extent permitted by law and subject to Section 3.6, Xencor may participate in communications and meetings with any Regulatory Authority to the extent the name and/or then-current Xencor logo is used on the drug product label and such labeling is being discussed in such communication or meeting. Notwithstanding MorphoSys’ obligations under this Article 3, MorphoSys shall not be required to share with Xencor any information which MorphoSys is not permitted to share with Xencor under the applicable laws or regulations of the Securities & Exchange Commission or other regulatory body of the US or elsewhere.